Nasdaq · CIK 0002035832
AKTS Aktis Oncology, Inc.
Insider trading from SEC Form 4. Last filing 20 d ago. Close $17.34 on Oct 12, 2026, +14% from the 52-week low and -46% from the high.
In brief
Aktis Oncology, Inc. (AKTS) has 13 SEC Form 4 filings on file from 11 insiders, the latest filed on Sep 24, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 3 open-market sells worth $455k, net -$455k.
11 open-market trades have been scored at AKTS. The newest: Akos Czibere (Chief Medical Officer) sold $259k of stock on Sep 23, 2026, filed Sep 24, 2026, scored 13 (weak), under a 10b5-1 plan. The largest of the 11 shown: EcoR1 Capital, LLC (director) bought $40M on Jan 12, 2026, scored 75 (notable). 3 insiders sold within 14 days of each other around Jul 20, 2026.
5 Form 144 notices of planned sales are on file, the latest filed Sep 23, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Aktis Oncology, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 13Weak | Akos Czibere Chief Medical Officer sell | $259k 12,500 shares | -100% | - | |
| 45Moderate | Ken Herrmann director sell | $119k 4,856 shares | -100% | +58% from low-26% from high | |
| 43Moderate | Ken Herrmann director sell | $77k 3,065 shares | -100% | +64% from low-23% from high | |
| 60Notable | Akos Czibere Chief Medical Officer sell | $1.4M 50,000 shares | -100% | +89% from low-11% from high | |
| 65Notable | Shulamit Ron-Bigger Chief Operating Officer sell | $1.4M 50,000 shares | -100% | +89% from low-11% from high | |
| 60Notable | Ansbert Gadicke owner buy | $20M 1,112,777 shares | +12% | 0% from low-3% from high | |
| 60Notable | Mpm Bioventures 2018, L.p. owner buy | $20M 1,112,777 shares | +12% | 0% from low-3% from high | |
| 68Notable | Todd Foley director, owner buy | $4.2M 232,870 shares | +6% | 0% from low-3% from high | |
| 75Notable | EcoR1 Capital, LLC director buy | $40M 2,222,222 shares | +98% | 0% from low-3% from high | |
| 68Notable | Helen Susan Kim director, owner buy | $15M 835,000 shares | +17% | 0% from low-3% from high | |
| 60Notable | Vida Ventures II, LLC owner buy | $15M 835,000 shares | +17% | 0% from low-3% from high |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 23, 2026 | Akos Czibere Officer | 25,000 0.05% of outstanding | $553k | Sep 23, 2026 | $1.4M |
| Jul 20, 2026 | KEN HERRMANN Director | 4,856 0.01% of outstanding | $119k | Jul 20, 2026 | $77k |
| Jul 17, 2026 | KEN HERRMANN Director | 3,065 0.01% of outstanding | $77k | Jul 17, 2026 | none |
| Jul 8, 2026 | SHULAMIT RON-BIGGER Officer | 50,000 0.09% of outstanding | $1.4M | Jul 8, 2026 | none |
| Jul 8, 2026 | AKOS CZIBERE Officer | 50,000 0.09% of outstanding | $1.4M | Jul 8, 2026 | none |
Transactions
The newest 50 of 76 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | Akos Czibere Chief Medical Officer | MOption exercise Common Stock10b5-1 | +12,500 | $4.95 | $62k | 12,500 | 20 d ago |
| Sep 23, 2026 | Akos Czibere Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -5,099 | $20.19 | $103k | 7,401 | 20 d ago |
| Sep 23, 2026 | Akos Czibere Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -7,401 | $21.03 | $156k | 0 | 20 d ago |
| Sep 23, 2026 | Akos Czibere Chief Medical Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,500 | $0.00 | $0 | 208,718 | 20 d ago |
| Jul 20, 2026 | Ken Herrmann director | MOption exercise Common Stock | +3,506 | $0.08 | $280 | 3,506 | Jul 21, 2026 |
| Jul 20, 2026 | Ken Herrmann director | MOption exercise Common Stock | +1,350 | $1.91 | $2,579 | 4,856 | Jul 21, 2026 |
| Jul 20, 2026 | Ken Herrmann director | SOpen-market sale Common Stock | -3,506 | $24.56 | $86k | 1,350 | Jul 21, 2026 |
| Jul 20, 2026 | Ken Herrmann director | SOpen-market sale Common Stock | -1,350 | $24.56 | $33k | 0 | Jul 21, 2026 |
| Jul 20, 2026 | Ken Herrmann director | MOption exercise Stock Option (Right to Buy)derivative | -3,506 | $0.00 | $0 | 0 | Jul 21, 2026 |
| Jul 20, 2026 | Ken Herrmann director | MOption exercise Stock Option (Right to Buy)derivative | -1,350 | $0.00 | $0 | 18,364 | Jul 21, 2026 |
| Jul 17, 2026 | Ken Herrmann director | MOption exercise Common Stock | +3,065 | $0.08 | $245 | 3,065 | Jul 20, 2026 |
| Jul 17, 2026 | Ken Herrmann director | SOpen-market sale Common Stock | -3,065 | $25.21 | $77k | 0 | Jul 20, 2026 |
| Jul 17, 2026 | Ken Herrmann director | MOption exercise Stock Option (Right to Buy)derivative | -3,065 | $0.00 | $0 | 3,506 | Jul 20, 2026 |
| Jul 8, 2026 | Akos Czibere Chief Medical Officer | MOption exercise Common Stock | +50,000 | $4.95 | $248k | 50,000 | Jul 10, 2026 |
| Jul 8, 2026 | Shulamit Ron-Bigger Chief Operating Officer | MOption exercise Common Stock | +50,000 | $3.66 | $183k | 50,000 | Jul 10, 2026 |
| Jul 8, 2026 | Shulamit Ron-Bigger Chief Operating Officer | SOpen-market sale Common Stock | -15,800 | $27.13 | $429k | 34,200 | Jul 10, 2026 |
| Jul 8, 2026 | Akos Czibere Chief Medical Officer | SOpen-market sale Common Stock | -14,800 | $27.13 | $401k | 35,200 | Jul 10, 2026 |
| Jul 8, 2026 | Akos Czibere Chief Medical Officer | SOpen-market sale Common Stock | -30,829 | $27.95 | $862k | 4,371 | Jul 10, 2026 |
| Jul 8, 2026 | Shulamit Ron-Bigger Chief Operating Officer | SOpen-market sale Common Stock | -30,000 | $27.94 | $838k | 4,200 | Jul 10, 2026 |
| Jul 8, 2026 | Akos Czibere Chief Medical Officer | SOpen-market sale Common Stock | -4,371 | $28.71 | $125k | 0 | Jul 10, 2026 |
| Jul 8, 2026 | Shulamit Ron-Bigger Chief Operating Officer | SOpen-market sale Common Stock | -4,200 | $28.75 | $121k | 0 | Jul 10, 2026 |
| Jul 8, 2026 | Shulamit Ron-Bigger Chief Operating Officer | MOption exercise Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 217,888 | Jul 10, 2026 |
| Jul 8, 2026 | Akos Czibere Chief Medical Officer | MOption exercise Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 221,218 | Jul 10, 2026 |
| Apr 15, 2026 | Glenn Gormley director | AGrant or award Stock Option (Right to Buy)derivative | +37,866 | $0.00 | $0 | 37,866 | Apr 16, 2026 |
| Jan 12, 2026 | Todd Foley director, owner | CConversion Common Stockindirect: See Footnote | +597,391 | - | - | 597,391 | Jan 14, 2026 |
| Jan 12, 2026 | Mpm Bioventures 2018, L.p. owner | CConversion Common Stockindirect: See Footnote | +1,314,262 | - | - | 1,655,971 | Jan 14, 2026 |
| Jan 12, 2026 | Ansbert Gadicke owner | CConversion Common Stockindirect: See Footnote | +1,314,262 | - | - | 1,655,971 | Jan 14, 2026 |
| Jan 12, 2026 | Ansbert Gadicke owner | CConversion Common Stockindirect: See Footnote | +5,914,197 | - | - | 7,570,168 | Jan 14, 2026 |
| Jan 12, 2026 | Mpm Bioventures 2018, L.p. owner | CConversion Common Stockindirect: See Footnote | +5,914,197 | - | - | 7,570,168 | Jan 14, 2026 |
| Jan 12, 2026 | Todd Foley director, owner | CConversion Common Stockindirect: See Footnote | +2,688,270 | - | - | 3,285,661 | Jan 14, 2026 |
| Jan 12, 2026 | Mpm Bioventures 2018, L.p. owner | CConversion Common Stockindirect: See Footnote | +1,577,119 | - | - | 9,147,287 | Jan 14, 2026 |
| Jan 12, 2026 | Todd Foley director, owner | CConversion Common Stockindirect: See Footnote | +716,872 | - | - | 4,002,533 | Jan 14, 2026 |
| Jan 12, 2026 | Ansbert Gadicke owner | CConversion Common Stockindirect: See Footnote | +1,577,119 | - | - | 9,147,287 | Jan 14, 2026 |
| Jan 12, 2026 | Todd Foley director, owner | POpen-market purchase Common Stockindirect: See Footnote | +232,870 | $18.00 | $4.2M | 4,235,403 | Jan 14, 2026 |
| Jan 12, 2026 | Mpm Bioventures 2018, L.p. owner | POpen-market purchase Common Stockindirect: See Footnote | +1,112,777 | $18.00 | $20M | 10,260,064 | Jan 14, 2026 |
| Jan 12, 2026 | Ansbert Gadicke owner | POpen-market purchase Common Stockindirect: See Footnote | +1,112,777 | $18.00 | $20M | 10,260,064 | Jan 14, 2026 |
| Jan 12, 2026 | Mpm Bioventures 2018, L.p. owner | CConversion Series Seed Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -5,000,000 | $0.00 | $0 | 0 | Jan 14, 2026 |
| Jan 12, 2026 | Ansbert Gadicke owner | CConversion Series Seed Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -5,000,000 | $0.00 | $0 | 0 | Jan 14, 2026 |
| Jan 12, 2026 | Todd Foley director, owner | CConversion Series Seed Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -2,272,727 | $0.00 | $0 | 0 | Jan 14, 2026 |
| Jan 12, 2026 | Mpm Bioventures 2018, L.p. owner | CConversion Series A Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -22,500,000 | $0.00 | $0 | 0 | Jan 14, 2026 |
| Jan 12, 2026 | Todd Foley director, owner | CConversion Series A Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -10,227,273 | $0.00 | $0 | 0 | Jan 14, 2026 |
| Jan 12, 2026 | Ansbert Gadicke owner | CConversion Series A Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -22,500,000 | $0.00 | $0 | 0 | Jan 14, 2026 |
| Jan 12, 2026 | Mpm Bioventures 2018, L.p. owner | CConversion Series B Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -6,000,000 | $0.00 | $0 | 0 | Jan 14, 2026 |
| Jan 12, 2026 | Todd Foley director, owner | CConversion Series B Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -2,727,273 | $0.00 | $0 | 0 | Jan 14, 2026 |
| Jan 12, 2026 | Ansbert Gadicke owner | CConversion Series B Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -6,000,000 | $0.00 | $0 | 0 | Jan 14, 2026 |
| Jan 12, 2026 | EcoR1 Capital, LLC director | CConversion Common Stockindirect: See Note | +2,270,879 | - | - | 2,270,879 | Jan 12, 2026 |
| Jan 12, 2026 | Helen Susan Kim director, owner | CConversion Common Stockindirect: See Footnote | +4,859,370 | - | - | 4,859,370 | Jan 12, 2026 |
| Jan 12, 2026 | Lloyd Mitchell Segal director | CConversion Common Stockindirect: See Footnote | +19,631 | - | - | 19,631 | Jan 12, 2026 |
| Jan 12, 2026 | Vida Ventures II, LLC owner | CConversion Common Stockindirect: See Footnote | +4,859,370 | - | - | 4,859,370 | Jan 12, 2026 |
| Jan 12, 2026 | Helen Susan Kim director, owner | POpen-market purchase Common Stockindirect: See Footnote | +812,455 | $18.00 | $15M | 5,671,825 | Jan 12, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Akos CzibereChief Medical Officer
- EcoR1 Capital, LLCowner, director
- Todd Foleyowner, other, director
- Ansbert Gadickeowner, other
- Glenn Gormleydirector
- Ken Herrmanndirector
- Helen Susan Kimdirector, owner
- Mpm Bioventures 2018, L.p.owner, other
- Shulamit Ron-BiggerChief Operating Officer
- Lloyd Mitchell Segaldirector, ceo, president, officer
- Vida Ventures II, LLCowner
Questions about AKTS
Answered from the filings on this page, as of the latest one.
Are insiders buying AKTS?
As of Sep 24, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 3 open-market sells worth $455k by 2 insiders at Aktis Oncology, Inc. in the last 90 days, net -$455k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade AKTS on the open market?
Akos Czibere (Chief Medical Officer) sold $259k of AKTS on Sep 23, 2026 and filed the Form 4 on Sep 24, 2026. InsiderTell scored 13 (weak), under a 10b5-1 plan.
How many insiders file Form 4 at Aktis Oncology, Inc.?
11 people have filed a Form 4 at Aktis Oncology, Inc., among them Akos Czibere (Chief Medical Officer), EcoR1 Capital, LLC (10% owner and director), Todd Foley (10% owner and director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.